Syros pharmaceuticals, inc. (SYRS)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Dec'15
Assets
Current assets:
Cash and cash equivalents

116,873

41,441

33,364

101,740

22,129

49,886

43,524

114,386

94,334

32,205

42,149

79,531

47,999

58,588

93,494

50,116

35,909

Marketable securities

5,003

49,975

74,774

19,978

53,737

49,793

69,707

9,980

27,407

39,844

39,799

11,990

22,495

25,005

-

-

-

Accounts receivable

-

20,000

-

-

-

-

-

-

-

-

-

-

551

867

-

-

-

Contract assets

1,635

158

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

2,184

2,649

2,244

2,012

1,259

1,417

1,675

2,585

1,436

917

1,026

1,669

1,460

1,048

1,387

2,037

540

Restricted cash, current portion

-

290

638

638

638

638

638

-

193

193

193

-

-

-

-

-

-

Total current assets

125,695

114,513

111,020

124,368

77,763

101,734

115,544

126,951

123,370

73,159

83,167

93,190

72,505

85,508

94,881

52,153

36,449

Property and equipment, net

15,756

15,210

11,147

5,443

3,897

3,861

3,908

3,275

3,565

3,938

4,127

4,508

4,546

4,850

4,603

4,773

4,799

Other long-term assets

776

490

933

889

1,103

881

892

863

875

1,101

1,093

850

489

482

443

3,537

1,900

Restricted cash, net of current portion

3,086

3,086

3,376

3,376

3,376

290

290

290

290

290

290

483

483

483

483

483

483

Right-of-use asset – operating lease

15,294

15,821

16,496

16,831

1,308

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets – financing leases

793

858

859

920

981

-

-

-

-

-

-

-

-

-

-

-

-

Total assets

161,400

149,978

143,831

151,827

88,428

106,766

120,634

131,379

128,100

78,488

88,677

99,031

78,023

91,323

100,410

60,946

43,631

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

4,636

5,853

8,043

1,759

2,632

3,309

2,671

1,263

1,717

2,283

1,846

1,348

2,377

2,415

4,039

1,645

5,035

Accrued expenses

6,843

10,646

11,204

10,057

9,086

13,893

11,159

8,935

8,980

9,728

-

-

-

6,115

-

-

-

Deferred revenue, current portion

-

-

-

-

-

-

7,075

7,098

10,272

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

6,958

5,201

3,989

-

3,834

4,040

2,504

Deferred revenue, current portion

6,795

5,739

1,114

1,661

1,848

1,926

-

-

-

-

-

-

-

550

-

-

-

Deferred rent, current portion

-

-

-

-

-

392

383

374

364

355

346

337

328

319

310

301

284

Financing and capital lease obligations, current portion

247

241

231

226

221

9

-

-

-

-

-

-

-

-

-

-

-

Operating lease obligation, current portion

1,287

1,037

1,978

1,629

1,192

-

-

-

-

-

-

-

-

-

-

-

-

Capital lease obligations, current portion

-

-

-

-

-

-

9

9

4

47

89

130

171

168

165

163

133

Total current liabilities

19,808

23,516

22,570

15,332

14,979

19,529

21,297

17,679

21,337

12,413

9,239

7,016

6,865

9,567

8,348

6,149

7,956

Deferred rent, net of current portion

-

-

7,076

9,295

-

353

456

552

649

745

839

926

1,013

1,101

1,185

1,263

1,420

Deferred revenue, net of current portion

20,681

22,639

7,614

7,625

7,900

8,276

4,020

4,409

1,610

-

-

-

-

-

-

-

-

Financing lease obligations, net of current portion

557

621

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing and capital lease obligations, net of current portion

-

-

648

708

766

22

-

-

-

-

-

-

-

-

-

-

-

Operating lease obligation, net of current portion

24,244

24,018

18,425

16,247

765

-

-

-

-

-

-

-

-

-

-

-

-

Debt, net of debt discount, long term

19,567

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted stock liability, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

-

Capital lease obligations, net of current portion

-

-

-

-

-

-

24

27

5

6

7

8

9

53

96

138

206

Commitments and contingencies (See Note 9)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2020 and December 31, 2019; 0 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

-

0

Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2020 and December 31, 2019; 45,690,718 and 43,367,801 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

45

43

43

43

34

34

34

34

32

26

26

26

23

23

23

3

2

Additional paid-in capital

386,704

372,100

367,764

365,329

297,982

296,100

294,329

292,461

274,230

220,606

218,540

217,200

182,897

181,844

181,049

7,706

5,547

Accumulated other comprehensive gain

3

24

21

4

8

-3

-13

-7

-34

-42

-10

-6

-13

-9

-

-

-

Accumulated deficit

-310,209

-292,983

-273,254

-253,461

-234,006

-217,545

-199,513

-183,776

-169,729

-155,266

-139,964

-126,139

-112,771

-101,256

-90,291

-76,122

-53,513

Total stockholders' equity

76,543

79,184

94,574

111,915

64,018

78,586

94,837

108,712

104,499

65,324

78,592

91,081

70,136

80,602

90,781

-68,413

-47,964

Total liabilities and stockholders' equity

161,400

149,978

143,831

151,827

88,428

106,766

120,634

131,379

128,100

78,488

88,677

99,031

78,023

91,323

100,410

60,946

43,631